286 related articles for article (PubMed ID: 22415852)
1. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL
Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852
[TBL] [Abstract][Full Text] [Related]
2. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
Liu Y; Dai B; Xu C; Fu L; Hua Z; Mei C
PLoS One; 2011; 6(12):e28915. PubMed ID: 22174924
[TBL] [Abstract][Full Text] [Related]
4. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.
Yuajit C; Muanprasat C; Gallagher AR; Fedeles SV; Kittayaruksakul S; Homvisasevongsa S; Somlo S; Chatsudthipong V
Biochem Pharmacol; 2014 Apr; 88(3):412-21. PubMed ID: 24518257
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
6. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
[TBL] [Abstract][Full Text] [Related]
7. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
8. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Yamaguchi T; Nagao S; Wallace DP; Belibi FA; Cowley BD; Pelling JC; Grantham JJ
Kidney Int; 2003 Jun; 63(6):1983-94. PubMed ID: 12753285
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
Liu Y; Dai B; Fu L; Jia J; Mei C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
[TBL] [Abstract][Full Text] [Related]
11. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
12. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Yamaguchi T; Reif GA; Calvet JP; Wallace DP
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F944-51. PubMed ID: 20810616
[TBL] [Abstract][Full Text] [Related]
14. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion.
Nantavishit J; Chatsudthipong V; Soodvilai S
Biochem Pharmacol; 2018 Aug; 154():175-182. PubMed ID: 29746821
[TBL] [Abstract][Full Text] [Related]
17. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
19. Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.
Parker MI; Nikonova AS; Sun D; Golemis EA
Cell Signal; 2020 Mar; 67():109497. PubMed ID: 31830556
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
Tonum K; Srimai N; Chabang N; Fongsupa S; Tuchinda P; Torres JA; Weimbs T; Soodvilai S
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
